Blockchain Registration Transaction Record

American Heart Association Launches Nationwide ATTR-CM Care Initiative

American Heart Association launches a nationwide initiative to improve early diagnosis and care for ATTR-CM, a life-threatening heart disease, with support from Alnylam Pharmaceuticals.

This initiative addresses a critical gap in healthcare by targeting ATTR-CM, a serious heart condition that is often underdiagnosed and can lead to heart failure and reduced life expectancy if untreated. By improving early diagnosis and coordinated care, it directly impacts patients by potentially extending survival, preserving physical function, and enhancing quality of life through timely access to treatments. For the broader public, it sets a precedent for tackling systemic issues in rare disease management, which could lead to better healthcare outcomes and reduced costs associated with late-stage interventions. As cardiovascular diseases remain a leading cause of death globally, efforts like this contribute to advancing medical practices and patient care standards.